Phico Therapeutics is developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.

Phico’s patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. SASPject™ is a new class of antibiotic which could provide many advantages over conventional antibiotic classes.

Early clinical development of first product, SASPject™ PT1.2 aimed at Staphylococcus aureus, including MRSA is backed by The Wellcome Trust. Other products in development target Clostridium difficile and Gram negative bacteria including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.